EverSource Wealth Advisors LLC Sells 4,946 Shares of Johnson & Johnson $JNJ

EverSource Wealth Advisors LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 25.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,700 shares of the company’s stock after selling 4,946 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $2,245,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. GFG Capital LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $35,000. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the first quarter valued at approximately $48,000. Vermillion & White Wealth Management Group LLC grew its stake in Johnson & Johnson by 66.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock worth $57,000 after buying an additional 150 shares in the last quarter. Finally, Pandora Wealth Inc. bought a new position in shares of Johnson & Johnson in the 1st quarter worth $65,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on JNJ. Scotiabank initiated coverage on shares of Johnson & Johnson in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 target price for the company. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a report on Monday, October 20th. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Four analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $202.10.

Johnson & Johnson Trading Down 1.5%

Shares of JNJ stock opened at $202.24 on Friday. The business has a 50-day moving average of $193.61 and a 200 day moving average of $174.90. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $207.81. The stock has a market capitalization of $487.25 billion, a PE ratio of 19.52, a P/E/G ratio of 2.29 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.6%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.